Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of Shingrix efficacy, safety, and immune persistence in older adults
2023-505255-51-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by GSK. Planned start Aug 2022; status: authorised.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2023-505255-51-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505255-51-00.